ISIS Income Statement

Click line-items for a historical chart and %
Revenue:
Research and development revenue under collaborative agreements 41.92M
Licensing and royalty revenue 1.44M
Total revenue 43.36M
Expenses:
Research and development 38.31M
General and administrative 3.42M
Total operating expenses 41.74M
Loss from operations 1.63M
Other income (expense):
Equity in net loss of Regulus Therapeutics Inc. 0
Investment income 376K
Interest expense -4.8M
Gain (loss) on investments, net 1.06M
Loss before income tax expense
Income tax expense
Net loss
Basic net loss (in dollars per share)
Diluted net loss (in dollars per share)
Shares used in computing basic net loss per share (in shares) 101.88M
Shares used in computing diluted net loss per share (in shares) 101.88M

Entities mentioned with ISIS

View All Entities